Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Press Releases
Filter articles using the following links
Financial press releases
Events & presentations
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
13 Jun 2019 - 16 Jun 2019
2019 SOE Congress, European Society of Ophthalmology, Nice, France
03 Jun 2019 - 06 Jun 2019
BIO International Convention, Philadelphia, PA (US)
29 May 2019
Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude
23 May 2019
GenSight Biologics to Host KOL Breakfast on May 23, 2019 in New York
23 May 2019
KOL Event to present Phase 3 REVERSE&RESCUE results of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON), New York City
21 May 2019
Annual General Meeting on June 11, 2019
15 May 2019
GenSight Biologics reports positive 96-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)
07 May 2019
GenSight Biologics announces positive Data Safety Monitoring Board review and continuation of PIONEER Phase I/II clinical trial of GS030 combining gene therapy and Optogenetics for the treatment of Retinitis Pigmentosa
06 May 2019
GenSight Biologics announces presentation of 72-week data from the REVERSE Phase III trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)
29 April 2019
GenSight Biologics Announces the Filing of its 2018 Annual Financial Report
View previous 9 articles
1
…
19
20
21
22
23
24
25
26
27
28
29
…
40
View next 9 articles
Go back to the page of the page